Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Accumulated Expenses (2016 - 2018)

Viking Therapeutics (VKTX) has disclosed Accumulated Expenses for 5 consecutive years, with $34000.0 as the latest value for Q1 2018.

  • Quarterly Accumulated Expenses changed N/A to $34000.0 in Q1 2018 from the year-ago period, while the trailing twelve-month figure was $34000.0 through Mar 2018, changed N/A year-over-year, with the annual reading at $22000.0 for FY2017, 36.95% down from the prior year.
  • Accumulated Expenses hit $34000.0 in Q1 2018 for Viking Therapeutics, up from $22000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $183611.0 in Q4 2015 to a low of $9982.0 in Q3 2017.
  • Historically, Accumulated Expenses has averaged $70009.8 across 5 years, with a median of $47113.5 in 2016.
  • Biggest five-year swings in Accumulated Expenses: tumbled 91.37% in 2016 and later soared 467.51% in 2017.
  • Year by year, Accumulated Expenses stood at $77222.0 in 2014, then surged by 137.77% to $183611.0 in 2015, then plummeted by 81.0% to $34894.0 in 2016, then crashed by 36.95% to $22000.0 in 2017, then surged by 54.55% to $34000.0 in 2018.
  • Business Quant data shows Accumulated Expenses for VKTX at $34000.0 in Q1 2018, $22000.0 in Q4 2017, and $9982.0 in Q3 2017.